Skip to main content
. 2025 Oct 3;11(5):e200299. doi: 10.1212/NXG.0000000000200299

Table 1.

Surveillance and Management Consensus Guidelines for Neurodevelopmental Features in Patients With PHTS (Based on the Second Stage of the Modified Delphi Process)

Statement Clinical recommendation Evidence grade and agreement, (%) Key details
Initial diagnosis and patient education
 N1/ND1 Educate patients/caregivers at diagnosis on potential neurodevelopmental/neuropsychiatric complications Weak (100) Complications to discuss: autism, mood/behavioral issues, sleep problems, IDD, learning differences, ADHD
Less common: Seizures, Lhermitte-Duclos disease, vasculopathy
Routine monitoring and screening
 ND3 Routinely measure head circumference (occipitofrontal) up to age 5 y Weak (83) At least annually
 ND4 Conduct developmental evaluation for young children at diagnosis; monitor ongoing if indicated Strong (83) Identify issues and guide accommodations/interventions
 ND5 Conduct comprehensive neuropsychological assessment at diagnosis Strong (83) Regardless of age, proactively identify issues and guide accommodations/interventions
 ND8 Assess fine and gross motor skills via formal neurologic examination at diagnosis (all ages) Strong (83) Regardless of age, at least by school age for early diagnoses. Can be part of developmental/neuropsychological assessment
 ND9 Assess sensory features Strong (83) Regardless of age; at least by school age for early diagnoses
 ND10 Offer assessment of psychological and behavioral functioning (all ages) Strong (83) At diagnosis, or at least by school age for early diagnoses, as clinically indicated
 ND11 Routinely screen for depression and anxiety symptoms Weak (80) Start as early as age 6 y (if indicated), at least by age 12 y. Screen at least annually, or more frequently
 ND16 Screen for and counsel about potential sleep issues Expert opinion (67) Includes insomnia, frequent arousals, RLS, reduced restful sleep, anxiety-related sleep disorders, OSA, and other sleep challenges
Targeted interventions and management
 ND2 Avoid routine mTOR inhibitors for neuropsychiatric/neurocognitive symptoms outside of clinical trials Strong (100) Use only if deemed clinically appropriate by the treating clinician
 ND6 Implement appropriate behavioral interventions for diagnosed ASD or significant autism symptoms Strong (100) Focus on improving social interaction, communication, and adaptive functioning
 ND7 Promptly conduct hearing and comprehensive speech-language evaluation for expressive/receptive language delays (e.g., nonspeaking and minimally verbal) Strong (100) By 3.5 y of age, identify specific issues and guide accommodations/interventions
 ND12 Refer individuals with psychological/behavioral difficulties to a licensed professional Strong (100) For treatment (behavioral support, psychotherapy, pharmacotherapy) or psychiatric evaluation, as indicated
 ND13 Use sleep hygiene and behavioral sleep medicine techniques as first-line treatment for insomnia Strong (100)
 ND14 Evaluate for OSA if headache/excessive daytime sleepiness OR if STOP-BANG criteria met. Strong (83) STOP-BANG criteria: ≥2 of snoring, tiredness, observed apnea, high BP. BMI >35, age >50 y, neck circumference >40 cm, male sex. If confirmed, treat with CPAP/other interventions via sleep specialist
 ND15 Follow relevant practice guidelines for sleep disorders in PHTS and autism spectrum disorder Weak (100)
 ND17 Minimize sedative/hypnotic medications (e.g., zolpidem) for sleep disturbances Expert opinion (100) Lack of scientific evidence for routine use in PHTS
 ND18 For established RLS, check serum ferritin levels Expert opinion (83) If ferritin <50−75 μg/L, trial oral iron supplementation (2–3 mo) before drug therapy

Abbreviations: ADHD = attention deficit hyperactivity disorder; ASD = autism spectrum disorder; BMI = body mass index; BP = blood pressure; CPAP = continuous positive airway pressure; IDD = intellectual developmental disorder; ND = neurodevelopmental; OSA = obstructive sleep apnea; PHTS = PTEN hamartoma tumor syndrome.